MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Mupirocin calcium

MCE 国际站：Mupirocin calcium

品牌：MedChemExpress (MCE)

货号：HY-B0958A

CAS 号：104486-81-9

生物活性：莫匹罗星（BRL-4910A，假单胞菌酸）钙是一种从荧光假单胞菌中分离得到的口服活性抗生素。莫匹罗星钙显然是通过可逆地抑制异亮氨酰转移RNA发挥其抗菌活性，从而抑制细菌蛋白质和RNA的合成[1][2]。

体外研究(In Vitro)：Mupirocin (BRL-4910A, Pseudomonic acid) calcium (0-100 μM; 48 h) shows antibacterial effect against staphylococci, streptococci and certain gram-negative bacteria, with MIC values range from 0.06-0.25 μg/mL (MIC50 =0.12 μg/mL, MIC90 =0.25 μg/mL)[1]. Mupirocin calcium is highly bound (95% bound) to human serum protein, thus results in activity inhibition in the presence of human serum[1]. Mupirocin calcium apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis[2]. Mupirocin calcium (2% ointment) reduces pro-inflammatory cytokines IL-1β and IL-17 level, decreases tumor necrosis factor-alpha (TNF-α) expression, and increases the leavel of vascular endothelial growth factor (VEGF)[4]. Mupirocin calcium inhibits MS (S. epidermidis ATCC 12228), MR (S. epidermidis (Se56-99)), and VIR (S. epidermidis (Se43-98)) with MICs of 0.25, 1.26, 1.59 mg/L[5]. Note: MIC, the minimum inhibition concentration. MCE尚未独立确认这些方法的准确性。 仅供参考。

体内研究(In Vivo)：MRSA: Meticillin-resistant Staphylococcus aureus Mupirocin (BRL-4910A, Pseudomonic acid) calcium is well absorbed after oral and parenteral administration but serum antibiotic concentrations were short-lived as a result of extensive degradation to the antibacterially inactive metabolite, monic acid A[1]. Mupirocin calcium (2% ointment; external administration; twice daily; 3-6 d) decreases the total bacterial loads in the skin lesions with either topical treatment[3]. Mupirocin calcium (2% ointment; external administration; 4 d) alleviates MRSA-infected pressure ulcers in mice[4]. Mupirocin calcium (100 mg/mL; s.c.; 7 d) exerts prevention efficacy against vascular prosthetic graft infection due to Staphylococcus epidermidis[5]. MCE尚未独立确认这些方法的准确性。 仅供参考。

分子量：520.66

Formula：C26H44CaO9

运输条件：美国大陆地区的室温；其他地区可能有所不同。

储存方式：请按照分析证书中推荐的条件储存产品。

文献引用：MCE 顾客使用本产品发表 1 篇科研文献

提供质量检测报告：Data Sheet、产品使用指南

产品活性：Mupirocin (BRL-4910A, Pseudomonic acid) calcium 可从 Pseudomonas fluorescens 中分离得到，是一种有口服活性的抗生素。Mupirocin calcium 通过可逆地抑制异亮氨酸转移 RNA，从而抑制细菌蛋白和 RNA 的合成而发挥抗菌作用。

相关产品：Oxacillin sodium salt  | Paromomycin sulfate  | Methicillin sodium salt  | Thiostrepton  | Sulfamonomethoxine  | Mupirocin  | Penicillin V Potassium  | Azaserine  | Penicillin V  | Dicloxacillin Sodium hydrate  | Orbifloxacin  | Oxacillin sodium salt (Standard)

热门产品线：抑制剂  | 稳定性同位素标记物  |  脂质  |  糖类

Trending products：Inhibitors  | Isotope-Labeled Compounds  |  Lipids  |  Saccharides

MCE 抑制剂:
MedChemExpress (MCE) 提供抑制剂、激动剂、拮抗剂、激活剂、调节剂、降解剂、配体和底物等多种生物活性化合物，可用于靶点功能验证、信号转导机制研究、细胞表型分析、疾病机制研究、药效评价及活性化合物筛选。

MedChemExpress 信号通路产品覆盖细胞凋亡、自噬、细胞周期与 DNA 损伤、表观遗传、GPCR/G 蛋白、免疫与炎症、JAK/STAT、MAPK/ERK、膜转运体与离子通道、代谢酶与蛋白酶、神经信号、NF-κB、PI3K/Akt/mTOR、PROTAC、蛋白酪氨酸激酶/受体酪氨酸激酶、干细胞/Wnt、TGF-β/Smad 及维生素 D/核受体等研究方向，为肿瘤、感染、炎症与免疫、神经系统疾病、代谢性疾病、心血管疾病和内分泌研究提供多维度的产品选择，助力客户发表文献超 80,000 篇。

相关产品可根据具体情况提供化学结构、作用靶点、生物活性、纯度、溶解度、体内外研究信息、参考文献及质量分析报告 (COA)等资料。

客户发表文献：
[1]. Nature. 2026 Sep;657(8131):549-558.
[2]. Nature. 2026 Sep;657(8132):755-764.
[3]. Nature. 2026 Sep;657(8133):1027-1034.
[4]. Nature. 2026 Sep;657(8131):477-486.
[5].Nature. 2026 Sep;657(8132):789-799.
[6]. Nature. 2026 Sep;657(8131):517-524.
[7]. Nature. 2026 Sep;657(8133):1045-1052.
[8]. Cell. 2026 Sep 14:S0092-8674(26)01003-2.
[9]. Cell. 2026 Sep 3;189(18):5688-5705.e13.
[10]. Cell. 2026 Sep 2:S0092-8674(26)00937-2.

参考文献：
[1]. Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27(4):495-8.
[2]. Parenti MA, et al. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm. 1987 Oct;6(10):761-70.
[3]. Vingsbo Lundberg C, et al. Efficacy of topical and systemic antibiotic treatment of meticillin-resistant Staphylococcus aureus in a murine superficial skin wound infection model. Int J Antimicrob Agents. 2013 Sep. 42(3):272-5.
[4]. Mohammad H, Abutaleb NS, Dieterly AM, Lyle LT, Seleem MN. Investigating auranofin for the treatment of infected diabetic pressure ulcers in mice and dermal toxicity in pigs. Sci Rep. 2021 May 25;11(1):10935.
[5]. Giacometti A, et al. Mupirocin prophylaxis against methicillin-susceptible, methicillin-resistant, or vancomycin-intermediate Staphylococcus epidermidis vascular-graft infection. Antimicrob Agents Chemother. 2000 Oct. 44(10):2842-4.